Connect with us

Business

Your FDs, RDs, SIPs Are Growing, But Are They Useless? The Biggest Mistake 90% Don’t Even Notice

Published

on

Your FDs, RDs, SIPs Are Growing, But Are They Useless? The Biggest Mistake 90% Don’t Even Notice


Personal Finance Tips: Most of us keep saving money through fixed deposits (FDs), recurring deposits (RDs), provident fund (PF) accounts or systematic investment plans (SIPs) without giving it the thought it actually deserves. The bank deduction goes through, the balance inches up, the graph rises and everything looks fine on the surface.

But underneath this rhythm sits a truth that people are saving diligently without knowing what that money is supposed to do for them. This is a money trap that almost everyone walks into.

Investments keep running, but the purpose disappears. The amounts grow, but the “why” behind them turns vague. Once that emotional connection breaks, the whole act becomes routine and lifeless.

Add Zee News as a Preferred Source


Why Does This Happen?

Most people say they are saving for retirement or putting money aside for the future. These answers sound responsible but reveal very little. What does retirement look like? What kind of future are we imagining? When the mind cannot see a clear picture, it refuses to bond with the goal. That is when investing becomes a cold task.

FDs continue because they have always existed. SIPs continue because the automatic deduction is fixed. After a point, this cycle becomes tiring. Savings continue, but the inner reason for saving slips out of sight.

Purpose Mapping

Purpose Mapping reminds you that money is not meant to lie dormant but to support the kind of life you want. It brings your financial decisions back into your emotional world.

Instead of thinking in numbers, you begin by imagining how you actually want your daily life to look. A person may say, “I want the freedom to shift to a smaller town by the age of 45,” or “I want to be able to take a six-month career break without fear or stress,” or even, “If something serious happens at home, I should not feel helpless.”

These statements breathe. They feel real because you can see them unfolding.

Once these lived goals come into focus, the structure of your investments naturally aligns with them. The SIP you invest in each month becomes the cushion for a future career pause. The FD becomes a tool for near-term needs. The emergency fund becomes a source of mental peace rather than an afterthought. At this stage, you are no longer saving out of habit; you are investing with intention.

The emotional link becomes even stronger when each part of your financial plan is tied to a feeling (freedom, safety, peace or control). When money stands for something human, the motivation behind saving never dries up. And when you keep your goals visible, sometimes literally, sometimes in the back of your mind, the process becomes far easier. You no longer feel that you are losing money to deductions; you feel that every deduction is building a specific life.

Life keeps changing, and so should your goals. A review every year helps your investments change in step with you. When your plans move with your life, saving no longer feels like a burden. It becomes a way of staying ready for the life you want to live.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

FDA vaccine head will step down in April after string of controversial decisions

Published

on

FDA vaccine head will step down in April after string of controversial decisions


The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, April 22, 2025.

Nathan Posner | Anadolu | Getty Images

A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the agency following multiple decisions that raised concerns within the industry.

Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency spokesperson confirmed on Friday. It is his second departure from the position: He briefly left the post in July following backlash over his regulatory decisions, and returned only two weeks later in August.

In a post on X, FDA Commissioner Marty Makary said the FDA will appoint a successor before Prasad returns next month to the University of California San Francisco, where he taught before taking the FDA position last year. Makary said Prasad “got a tremendous amount accomplished” during his tenure at the agency.

Prasad’s decision to step down comes after criticism of the FDA mounted within the biotech and pharmaceutical industry and among former health officials. In the past year, the agency has denied or discouraged the approval applications of at least eight drugs, according to RTW Investments, after taking issue with data the companies used to support their applications. The FDA also initially refused to review Moderna’s flu shot before it later reversed course.

All of those companies accused the FDA of reversing previous guidance about the evidence they could use to back their applications, sparking criticism within the industry that an unreliable regulatory process could stifle development of drugs for hard-to-treat diseases.

A former FDA official who spoke to CNBC on the condition of anonymity to speak freely on the issue called the reversals the worst kind of regulatory uncertainty because companies say they are being told one thing and then experience another.

In a statement earlier Friday, an FDA spokesperson said there was “no regulatory uncertainty,” adding the agency “makes decisions based on the evidence, but does not make assurances about outcomes.” The spokesperson said the FDA is “conducting rigorous, independent reviews and not rubber-stamping approvals.”

The most recent controversy came after the FDA discouraged UniQure from applying for expedited approval of its experimental treatment for Huntington’s disease.

The agency, which underwent staff cuts and an overhaul under Health and Human Services Secretary Robert F. Kennedy Jr., has faced broader backlash for its drug and vaccine approvals process. Critics have worried the agency could stifle the development of new treatments and risk the safety of patients.

The Wall Street Journal earlier reported Prasad’s departure.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Business

Oil price at two-year high after Qatar minister warns all Gulf production could stop

Published

on

Oil price at two-year high after Qatar minister warns all Gulf production could stop



Energy Minister Saad al-Kaabi says oil could hit $150 a barrel if the Iran conflict continues over the coming weeks.



Source link

Continue Reading

Business

Govt increases petrol, diesel prices by Rs55 per litre amid Middle East tensions – SUCH TV

Published

on

Govt increases petrol, diesel prices by Rs55 per litre amid Middle East tensions – SUCH TV



The federal government has raised petrol prices by Rs55 per litre as surging global oil prices, fuelled by the US‑Israel war with Iran, put pressure on domestic energy costs.

The announcement was made by Petroleum Minister Ali Pervaiz Malik in a press conference alongside DPM Ishar Dar and Finance Minister Muhammad Aurangzeb.

This marks the first weekly review of fuel prices since regional tensions threatened a major share of global energy flows following the closure of the Strait of Hormuz.

Previously, the federal government adjusted petroleum prices on a fortnightly basis.



Source link

Continue Reading

Trending